Testing previous model predictions against new data on human papillomavirus vaccination program outcomes

BMC Research Notes

Karen Canfell¹  Megan A Smith² 

[1] Lowy Cancer Research Centre, Prince of Wales Clinical School, University of New South Wales, Sydney, NSW 2052, Australia;School of Public Health, University of Sydney, Sydney, NSW 2006, Australia

关键词: Australia;    Mathematical model;    Immunization program;    Vaccination;    HPV;    Human papillomavirus;   

Others  :  1134417
DOI  :  10.1186/1756-0500-7-109

 received in 2013-05-27, accepted in 2014-02-21,  发布年份 2014

【 摘 要 】

Background

Vaccination against human papillomavirus (HPV), predominantly targeting young females, has been introduced in many countries. Decisions to implement programs, which have involved substantial investment by governments, have in part been based on findings from cost-effectiveness models. Now that vaccination programs have been in place for some years, it is becoming possible to observe their effects, and compare these with model effectiveness predictions made previously.

Findings

Australia introduced a publicly-funded HPV vaccination program in 2007. Recently reported Australian data from a repeat cross-sectional survey showed a substantial (77%) fall in HPV16 prevalence in women aged 18–24 years in 2010–2011, compared to pre-vaccination levels. We have previously published model predictions for the population-wide reduction in incident HPV16 infections post-vaccination in Australia. We compared prior predictions from the same model (including the same assumed uptake rates) for the reduction in HPV16 prevalence in women aged 18–24 years by the end of 2010 with the observed data. Based on modelled vaccine uptake which is consistent with recent data on three-dose uptake (78% at 12–13 years; lower uptake in older catch-up age cohorts), we had predicted a 70% reduction in prevalence in 18–24 year old females by the end of 2010. Based on modelled vaccine uptake consistent with recent national data for two-dose coverage and similar to that reported by women in the cross-sectional study, we had predicted a 79% reduction.

Conclusions

A close correspondence was observed between the prior model predictions and the recently reported findings on the rapid drop in HPV prevalence in Australia. Because broadly similar effectiveness predictions have been reported from other models used for cost-effectiveness predictions, this provides reassurance that the substantial public investment in HPV vaccination has been grounded in valid estimates of the effects of vaccination.

【 授权许可】

   
2014 Smith and Canfell; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Budget 2007–08, budget paper No. 2, Part 2: expense measures http://www.budget.gov.au/2007-08/bp2/html/expense-20.htm webcite
• [2]Health budget 2007–2008: national immunisation program – implementation of the human papillomavirus vaccination program http://www.health.gov.au/internet/budget/publishing.nsf/Content/budget2007-hfact26.htm webcite
• [3]Canfell K, Chesson H, Kulasingam SL, Berkhof J, Diaz M, Kim JJ: Modeling preventative strategies against human papillomavirus-related disease in developed countries. Vaccine 2012, 30(Suppl 5):F157-F167.
• [4]IARC: IARC monographs on the evaluation of carcinogenic risks to humans. Volume 100B. Human papillomaviruses. Volume 100B. Lyon, France: IARC; 2012.
• [5]Donovan B, Franklin N, Guy R, Grulich AE, Regan DG, Ali H, Wand H, Fairley CK: Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis 2011, 11(1):39-44.
• [6]Ali H, Donovan B, Wand H, Read TR, Regan DG, Grulich AE, Fairley CK, Guy RJ: Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ 2013, 346:f2032.
• [7]Brotherton JM, Fridman M, May CL, Chappell G, Saville AM, Gertig DM: Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 2011, 377(9783):2085-2092.
• [8]Australian Institute of Health and Welfare: Cervical screening in Australia 2009–2010. Cancer series 67. Cat. no. CAN 63. Canberra: AIHW; 2012.
• [9]Tabrizi SN, Brotherton JM, Kaldor JM, Skinner SR, Cummins E, Liu B, Bateson D, McNamee K, Garefalakis M, Garland SM: Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis 2012, 206(11):1645-1651.
• [10]Brotherton JML, Murray SL, Hall M, Andrewartha LK, Banks CA, Meijer D, Pitcher HC, Scully MM, Molchanoff L: Human papillomavirus vaccine coverage among female Australian adolescents: success of the school based approach. Med J Aust 2013. in press
• [11]Brotherton J, Gertig D, Chappell G, Rowlands L, Saville M: Catching up with the catch-up: HPV vaccination coverage data for Australian women aged 18–26 years from the National HPV Vaccination Program Register. Commun Dis Intell 2011, 35(2):197-201.
• [12]Smith MA, Lew JB, Walker RJ, Brotherton JM, Nickson C, Canfell K: The predicted impact of HPV vaccination on male infections and male HPV-related cancers in Australia. Vaccine 2011, 29(48):9112-9122.
• [13]Smith MA, Canfell K, Brotherton JM, Lew JB, Barnabas RV: The predicted impact of vaccination on human papillomavirus infections in Australia. Int J Cancer 2008, 123(8):1854-1863.
• [14]Walker R, Nickson C, Lew JB, Smith M, Canfell K: A revision of sexual mixing matrices in models of sexually transmitted infection. Stat Med 2012, 31(27):3419-3432.
• [15]Garland SM, Brotherton JM, Condon JR, McIntyre PB, Stevens MP, Smith DW, Tabrizi SN: Human papillomavirus prevalence among indigenous and non-indigenous Australian women prior to a national HPV vaccination program. BMC Med 2011, 9:104. BioMed Central Full Text
• [16]Kreime AR, Gonzalez P, Katki HA, Porras C, Schiffman M, Rodriguez AC, Solomon D, Jimenez S, Schiller JT, Lowy DR, van Doorn LJ, Struijk L, Quint W, Chen S, Wacholder S, Hildesheim A, Herrero R: Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst 2011, 103(19):1444-1451.
• [17]Dobson S, McNeil S, Dionne M, Dawar M, Ogilvie G, Krajden M, Sauvageau C, Scheifele D, Kollmann T, Halperin S, Langley J, Bettinger J, Singer J, Money D, Miller D, Naus M, Marra F, Young E: Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: A randomized clinical trial. JAMA 2013, 309(17):1793-1802.
• [18]Immunise Australia Program - Human Papillomavirus (HPV) http://www.health.gov.au/internet/immunise/publishing.nsf/Content/immunise-hpv webcite
• [19]Australian Bureau of Statistics: Population by Age and Sex, Australian States and Territories, Jun 2002 to Jun 2007. Volume Catalogue number 3201.0. Canberra; 2008.
• [20]Gertig DM, Brotherton JML, Saville AM: Measuring human papillomavirus (HPV) vaccination coverage and the role of the National HPV Vaccination Program Register, Australia. Sex Health 2011, 8:171-178.
• [21]Brisson M, van de Velde N, Franco EL, Drolet M, Boily MC: Incremental impact of adding boys to current human papillomavirus vaccination programs: role of herd immunity. J Infect Dis 2011, 204(3):372-376.
• [22]Bogaards JA, Coupe VM, Xiridou M, Meijer CJLM, Wallinga J, Berkhof J: Long-term Impact of Human Papillomavirus Vaccination on Infection Rates, Cervical Abnormalities, and Cancer Incidence. Epidemiology 2011, 22(4):505-515.
• [23]Regan DG, Philp DJ, Hocking JS, Law MG: Modelling the population-level impact of vaccination on the transmission of human papillomavirus type 16 in Australia. Sex Health 2007, 4(3):147-163.
• [24]Caro JJ, Briggs AH, Siebert U, Kuntz KM: Modeling good research practices–overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1. Value Health 2012, 15(6):796-803.